Syndex Bio

📍 Cambridge, United Kingdom🗓 Founded 2022👥 27 employees💰 Last funded Oct 2025
Biotechnology Research🌐 syndex.bio
Website LinkedIn
mcPCR: methyl copying PCR. mcPCR is our novel and proprietary platform technology that preserves DNA methylation during DNA amplification. The method is analogous to traditional PCR, which efficiently and accurately copies the four-base code of DNA. But PCR cannot amplify the 5mC signal. By overcoming this fundamental limitation, mcPCR copies the original DNA methylation patterns and the underlying four-base code. This will enable simpler, faster and more sensitive analysis of methylated DNA even from the most limiting of clinical samples.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2022
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Syndex Bio?
Syndex Bio has 1 investors on record on gritt.io, 1 mid-stage.
When did Syndex Bio last raise funding?
The most recent investment in Syndex Bio recorded on gritt.io was in October 2025.
When was Syndex Bio founded?
Syndex Bio was founded in 2022.
What industry is Syndex Bio in?
Syndex Bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Syndex Bio based?
Syndex Bio is headquartered in Cambridge, United Kingdom.